Silodosin is a drug that is used to treat symptoms associated with benign prostatic hyperplasia (BPH). It belongs to the group of alpha-1-adrenoreceptor antagonists.

Benign prostatic hyperplasia (BPH) is a common condition in older men. It occurs when the prostate, a gland below the bladder, increases in size and presses on the urethra. Possible symptoms include difficulty urinating, weak urine flow and frequent urge to urinate.

The exact cause of BPH is not fully understood, but it is thought to be influenced by hormonal changes that occur as men age. It is thought that an increase in the level of dihydrotestosterone (DHT), a hormone derived from testosterone, stimulates the growth of prostate cells. This leads to an enlargement of the prostate and thus to the symptoms of BPH.

Graphic structural formula of the active substance silodosin

Drugs with Silodosin

Drug Substance(s) Authorisation holder
Urorec 8 mg hard capsules Silodosin Recordati Ireland Ltd.
Urorec 4 mg hard capsules Silodosin Recordati Ireland Ltd.
Silodyx 8 mg hard capsules Silodosin Recordati Ireland Ltd.
Silodyx 4 mg hard capsules Silodosin Recordati Ireland Ltd.


Prostatic smooth muscle tone is regulated by the α-adrenoceptor subtype α1A. Silodosin is an α1-adrenoceptor antagonist with the highest selectivity for the α1A-adrenoceptor subtype. By blocking the α1A-adrenoceptor signaling pathway, silodosin promotes smooth muscle relaxation in the prostate and urethra, improving symptoms of BPH. Silodosin also acts on the afferent nerves in the bladder and can also relieve bladder overactivity and congestion symptoms.

Silodosin is metabolized in the liver and rapidly absorbed after oral administration. The bioavailability, i.e. the percentage of the active ingredient available in the blood, is 32%. The half-life, i.e. the time the body needs to excrete half of the active substance, is 13 hours. The maximum plasma concentration (Cmax), i.e. the maximum concentration of the active ingredient in the blood plasma (liquid cell-free part of the blood), is reached after about 3 hours. When taken with high-fat food, the maximum plasma concentration is reduced by about 20 - 40 % and the time to reach this concentration is delayed by about 1 hour.

The apparent volume of distribution is about 50 L. Plasma protein binding is about 97 %. The enzyme mainly responsible for metabolization is UGT2B7. Other enzymes involved in metabolism are alcohol dehydrogenases, aldehyde dehydrogenases and CYP3A4. Slightly more than half of the dose is excreted in the stool, while around 30% is excreted in the urine.


Always take silodosin exactly as described in the package leaflet or as advised by your doctor.

The recommended dosage is 8 mg per day.

Initially, the usual dose is usually 4 mg per day and is increased to 8 mg per day during the course of therapy if necessary.

If kidney function is impaired, a reduced dosage of 4 mg may be necessary.

Silodosin should, if possible, always be taken at the same time and with a meal.

Side Effects

The following side effects may occur:

Very common:

  • Ejaculation disorders
  • Reduction of sperm count in the ejaculate and reversible impairment of fertility




Frequency unknown:

  • Floppy iris syndrome during cataract surgery


Interactions may occur if the following medicines are taken at the same time:

  • Medication that lowers blood pressure
  • Medication against fungal infections
  • Medication for the treatment of AIDS
  • Medication used after organ transplants
  • Medication for the treatment of erectile dysfunction
  • Medication for the treatment of epilepsy
  • Rifampicin


Silodosin must NOT be taken in the following cases

  • in case of allergy to silodosin

Age Restriction

Silodosin should only be used from the age of 18.

Pregnancy & Lactation

As silodosin is used exclusively in men, no data are available on its use during pregnancy and breastfeeding. Silodosin should not be taken by women.

History to the active ingredient

Silodosin was developed by the Japanese companies Kissei Pharmaceutical and Daiichi Sankyo and was first approved in Japan in 2006. The substance was approved in the USA in 2008. Approvals were granted in the EU and Switzerland in 2010 and 2016 respectively.

Chemical & physical properties

ATC Code G04CA04
Formula C25H32F3N3O4
Molar Mass (g·mol−1) 495,53
Physical State solid
Density (g·cm−3) 1,2
Melting Point (°C) 105–109
Boiling Point (°C) 601,4
PKS Value 14,87
CAS Number 160970-54-7
PUB Number 5312125
Drugbank ID DB06207

Editorial principles

All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Thomas Hofko

Thomas Hofko

Thomas Hofko is in the final third of his bachelor's degree in pharmacy and is an author and lecturer on pharmaceutical topics. He is particularly interested in the fields of clinical pharmacy and phytopharmacy.

The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.


Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über medikamio GmbH & Co KG und sein/ihr Internet-Angebot: This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.